Combination Therapy for Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 707
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Despite advances in diagnosis and treatment, the prognosis for HCC patients remains unsatisfactory, with limited curative options available. Combination therapy, involving the use of multiple treatment modalities simultaneously or sequentially, has emerged as a promising strategy to improve patient outcomes. These may include surgical interventions, tumor ablation, transarterial chemoembolization (TACE), transarterial chemoinfusion (HAIC), radiation therapy, systemic therapies and others. In this Special Issue, we will address the challenges and future directions of combination therapy for HCC. These may encompass novel combination strategies and potential synergies, with emerging therapies such as molecular targeted agents and immune checkpoint inhibitors. The goal of this Special Issue is to gather a comprehensive collection of articles that explore the various aspects of combination therapy for HCC, by reviewing the latest research, clinical trials and expert opinions. Here, we aim to provide clinicians, researchers and allied professionals with valuable insights into the current landscape of combination therapy approaches, their efficacy and future directions. By examining the underlying rationale, exploring various treatment modalities and addressing future perspectives, this issue strives to contribute to the advancement of combination therapy strategies, ultimately improving outcomes for patients with HCC.
Dr. Toshihiro Tanaka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- combination therapy
- multidisciplinary therapy
- outcomes
- prognosis
